Observational studyMedicine2026
Prognostic value of systemic inflammatory markers in patients with malignancy-associated pulmonary thromboembolism: A retrospective observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary thromboembolism (PTE) is a severe and potentially fatal complication in patients with malignancy. Systemic inflammation plays an important role in both cancer progression and thrombogenesis. This study aimed to evaluate the association of systemic inflammatory indices with in-hospital mortality and clinical risk classification in patients with malignancy-associated PTE. This retrospective study included 75 adult patients diagnosed with both malignancy and PTE at a tertiary chest diseases center between February 2018 and June 2025. Demographic characteristics, cancer types, laboratory values at diagnosis, treatment details, and clinical outcomes were recorded. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), lymphocyte-to-CRP ratio (LCRPR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated from blood samples obtained at diagnosis. The primary outcome was in-hospital mortality, and the secondary outcome was the association between systemic inflammatory markers and ESC PTE clinical risk classification. The mean age was 69.5 ± 11.8 years, and 56% of patients were male. Lung (24%), colorectal (13.3%), and breast (9.3%) cancers were the most common malignancies. In-hospital mortality was 20%. Neutrophil count (P = .026), NLR (P = .032), and lactate (P = .027) were significantly higher in patients who died during hospitalization. ROC analysis identified an NLR cutoff value of 4.95, with a sensitivity of 86.7% and a specificity of 51.7%. Neutrophil count and SIRI were significantly higher in the intermediate-risk group (P = .036 and P = .049, respectively), whereas troponin was highest in the high-risk group (P < .001). Neutrophil count, NLR, and lactate levels were associated with in-hospital mortality in patients with malignancy-associated PTE. Neutrophil count and SIRI were also associated with ESC clinical risk classification. These findings should be considered exploratory and require validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.